BioArctic & Biogen
8 shared events · Importance 3 · Last updated Sep 01, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
BioArctic: BioArctic receives royalties from Leqembi sales; Q2 2026 royalty of SEK 179 million represents 10% growth, boosting revenue outlook.
Biogen: Biogen is a partner in Leqembi commercialization; the sales results contribute to its Q2 2026 report.
Jul 29, 2026 · 6 articles
Regulatory
BioArctic: BioArctic is the inventor of Leqembi and receives royalties on global sales. The Canadian reimbursement recommendation is a positive development that could increase future revenue.
Biogen: Biogen is a partner in the development and commercialization of Leqembi, and the Canadian recommendation could positively affect its revenue from the drug.
Sep 01, 2026 · 6 articles
Business
BioArctic: Inventor of lecanemab; entitled to royalties and sales milestones from Eisai. The US launch of Leqembi Iqlik strengthens its commercial prospects.
Biogen: Joint development and commercialization partner for lecanemab; benefits from increased sales.
Aug 24, 2026 · 6 articles
Tech
BioArctic: BioArctic is the central actor, announcing the first Swedish patient treated with Leqembi and holding Nordic commercialization rights with Eisai. The launch supports its royalty and milestone revenue stream, though the negative NT-radet reimbursement recommendation limits near-term Swedish sales.
Biogen: Biogen is a partner in the joint development and commercialization agreement for lecanemab and co-sponsors the AHEAD 3-45 study, giving it indirect exposure to the Swedish launch.
Sep 22, 2026 · 7 articles
Business
BioArctic: As the inventor of Lecanemab and a partner in its development and commercialization, BioArctic stands to benefit significantly from the projected sales, receiving royalties and milestone payments. This event positively impacts its financial outlook.
Biogen: Biogen is a joint development and commercialization partner for Lecanemab, participating in clinical studies. While not the primary focus of this sales forecast, it benefits from the drug's success.
May 25, 2026 · 7 articles
Business
BioArctic: BioArctic, in collaboration with Eisai, developed Lecanemab and is set to receive approximately SEK 880 million in royalties from the projected sales, indicating a positive financial outlook for the company.
Biogen: Biogen entered into a joint development and commercialization agreement for lecanemab with Eisai in 2014 and is involved in the AHEAD 3-45 clinical study.
May 15, 2026 · 6 articles
Tech
BioArctic: Greta Duréel has consulted for BioArctic, but no direct impact from this study.
Biogen: Greta Duréel has consulted for Biogen, but no direct impact from this study.
Aug 12, 2026 · 14 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how BioArctic and Biogen interact across events, view sentiment trends, and discover connected entities.
Open Dashboard